Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Advances in Relapsed/Refractory Myeloma: Keeping Pace With a Rapidly Evolving Treatment Landscape
  • CME

Credits Available
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: June 8, 2022 Expiration: June 7, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics
Regeneron Pharmaceuticals, Inc.
Paul G. Richardson, MD
Program Director
Natalie S. Callander, MD
Noopur Raje, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement therapeutic strategies with emerging agents for patients with R/R MM based on the available data and individual patient and disease characteristics
  • Explain the mechanisms of action of novel and emerging classes of agents for R/R MM
  • Assess the efficacy and safety evidence of novel combination therapeutic regimens for patients with R/R MM
  • Identify treatment-related symptoms associated with new targeted therapies in patients with R/R MM to create management strategies
  • Select patients with R/R MM who would be eligible for enrollment on clinical trials

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Paul G. Richardson, MD

R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research

Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Paul G. Richardson, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb/Celgene, Karyopharm, Oncopeptides, and Takeda and has served on advisory boards for AstraZeneca, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Protocol Intelligence, Regeneron, Sanofi, Secura Bio, and Takeda.

Faculty

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has no relevant conflicts of interest to report.
Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Noopur Raje, MD, has disclosed that she has received funds for research support from 2Seventy Bio and consulting/advisory/speaker fees from Amgen, Bristol-Myers Squibb, Bluebird, Caribou Biosciences Celgene, GSK, Immuneel, Janssen, Merck, Millennium, Novartis, Pfizer, Sanofi, and Takeda.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.
Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Brian Purves, PharmD, MBA
Brian Purves, PharmD, has disclosed that he has previously received salary from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals who treat patients with multiple myeloma.

Goal

The goal of this activity is to improve the knowledge and competence of learners in selecting individualized treatments for patients with multiple myeloma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 08, 2022, through June 07, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Advances in Relapsed/Refractory Myeloma: Keeping Pace With a Rapidly Evolving Treatment Landscape
  • CME

Loading...
In this on-demand webcast from a live symposium, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD explore the latest advances in new and emerging therapies for patients with relapsed or refractory multiple myeloma.
Paul G. Richardson, MD
Program Director
Natalie S. Callander, MD
Noopur Raje, MD
Physicians: maximum of 2.0 AMA PRA Category 1 Credits
Released: June 8, 2022 Expiration: June 7, 2023

Related Content

Experts address audience questions from a live symposium on AML treatment strategies and future therapy directions, from Clinical Care Options (CCO)

Daniel Pollyea, MD, MS
Program Director
Courtney DiNardo, MD, MSCE Eytan M. Stein, MD
Released: January 24, 2023

Clinical Care Options (CCO): Expertos repasan los principales datos sobre LLC y LCM de las juntas de ASCO, EHA, la Conferencia Pan-PacĂ­fico sobre Linfomas, ESMO y SOHO de 2022

Othman Al-Sawaf, MD Matthew S. Davids, MD, MMSc Toby Eyre, MBChB, MD Christopher R. Flowers, MD, MS Brad S. Kahl, MD Kami Maddocks, MD Anthony Mato, MD, MSCE Lydia Scarfò, MD Julie M. Vose, MD, MBA Released: January 23, 2023

Downloadable resource designed to serve as a helpful guide for healthcare professionals on newer therapies for patients with follicular lymphoma, from Clinical Care Options (CCO)

Released: January 20, 2023

Downloadable slideset on recent advances in the clinical management of patients with CLL, from Clinical Care Options (CCO)

Jennifer R. Brown, MD, PhD Jeff Sharman, MD Released: January 19, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Karyopharm Therapeutics
Regeneron Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings